RANKL: A therapeutic target for bone destruction in rheumatoid arthritis

Sakae Tanaka, Yoshiya Tanaka, Naoki Ishiguro, Hisashi Yamanaka, Tsutomu Takeuchi

研究成果: Review article査読

34 被引用数 (Scopus)

抄録

Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterized by progressive joint destruction. Recent studies have indicated the critical involvement of osteoclasts in bone destruction in RA. The osteoclast differentiation factor receptor activator of NF-κB ligand (RANKL), which belongs to the tumor necrosis factor superfamily, plays a critical role in osteoclast differentiation and bone destruction in RA. Denosumab, an antibody against human RANKL, efficiently suppressed the progression of bone erosion in RA patients in randomized controlled studies, and is considered as a putative therapeutic option for preventing bone destruction in RA.

本文言語English
ページ(範囲)9-16
ページ数8
ジャーナルModern rheumatology
28
1
DOI
出版ステータスPublished - 2018 1 2

ASJC Scopus subject areas

  • リウマチ学

フィンガープリント

「RANKL: A therapeutic target for bone destruction in rheumatoid arthritis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル